| Trade Names: | |
| Synonyms: | |
| Status: | Approved (2017) |
| Entry Type: | Protein |
| Molecule Category: | UNKNOWN |
| ATC: | A10BJ06 |
| UNII: | 53AXN4NNHX |
| Action | Mechanism of Action | Reference |
|---|---|---|
| AGONIST | Glucagon-like peptide 1 receptor agonist |
| Primary Target | |
|---|---|
| GLP-1 receptor |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Membrane receptor
Family B G protein-coupled receptor
Peptide receptor (family B GPCR)
Glucagon-like receptor
Glucagon-like peptide receptor
|
0.0062-0.052 | 0.13-357 | 5.36-441 | - | - |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Alzheimer Disease | 3 | D000544 | ClinicalTrials |
| Diabetes Mellitus, Type 1 | 3 | D003922 | ClinicalTrials |
| Pseudotumor Cerebri | 3 | D011559 | ClinicalTrials |
| Non-alcoholic Fatty Liver Disease | 3 | D065626 | ClinicalTrials |
| Non-alcoholic Fatty Liver Disease | 3 | D065626 | ClinicalTrials |
| Coronary Disease | 3 | D003327 | ClinicalTrials |
| Klinefelter Syndrome | 3 | D007713 | ClinicalTrials |
| Cardiovascular Diseases | 3 | D002318 | ClinicalTrials |
| Nutrition Disorders | 3 | D009748 | ClinicalTrials |
| Diabetic Nephropathies | 2 | D003928 | ClinicalTrials |
| Tobacco Use Disorder | 2 | D014029 | ClinicalTrials |
| Substance-Related Disorders | 2 | D019966 | ClinicalTrials |
| Ischemic Stroke | 2 | D000083242 | ClinicalTrials |
| Alcoholism | 2 | D000437 | ClinicalTrials |
| Depressive Disorder, Major | 2 | D003865 | ClinicalTrials |
| Polycystic Ovary Syndrome | 2 | D011085 | ClinicalTrials |
| Liver Diseases | 2 | D008107 | ClinicalTrials |
| Asthma | 2 | D001249 | ClinicalTrials |
| Parkinson Disease | 2 | D010300 | ClinicalTrials |
| Bone Diseases, Metabolic | 1 | D001851 | ClinicalTrials |
| Resources | Reference |
|---|---|
| CAS NUMBER | 910463-68-2 |
| ChEMBL | CHEMBL2108724 |
| FDA SRS | 53AXN4NNHX |
| Guide to Pharmacology | 9724 |
| PubChem | 56843331 |